Iowa City, IANCT06395402Now EnrollingIRB Ready

Neuroendocrine Tumors Clinical Trial in Iowa City, IA

Access cutting-edge neuroendocrine tumors treatment through this phase 2 clinical trial at a research site in Iowa City. Study-provided care at no cost to qualified participants.

Sponsored by University of Iowa

Quick Self-Assessment

See if you qualify for this Iowa City location

Preparing your pre-screening questions…

Expert Care in Iowa City

Access neuroendocrine tumors specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related neuroendocrine tumors treatment provided free

Apply for This Iowa City Location

Check if you qualify for this neuroendocrine tumors clinical trial in Iowa City, IA

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to Iowa City

    Convenient for IA residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit Iowa City site if eligible
  4. 4Begin participation

About This Neuroendocrine Tumors Study in Iowa City

The goal of this study is to learn if individualized dosimetry-based prescribing of Lutetium-177 DOTATATE (Lutathera, Novartis Pharmaceuticals) improves treatment outcomes for adults with unresectable neuroendocrine tumors. To investigate this, study participants will: * Undergo Somatostatin Receptor (SSTR) positron emission tomography (PET) imaging, such as a DOTATOC PET/CT scan * Be randomized to receive standard treatment (as per FDA guidelines) or investigational treatment (customized dosing of Lutathera based upon dosimetry) * Undergo blood tests for 4 to 8 weeks after each Lutathera treatment * Complete patient reported outcome questionnaires * Visit the clinic for follow-up about every 8 weeks.

Sponsor: University of Iowa

Who Can Participate

Inclusion Criteria

Provision of signed and dated informed consent form.
Stated willingness to comply with all study procedures and availability for the duration of the study.
Aged ≥ 18 years at time of consent.
Pathologically confirmed (histology or cytology) malignant neoplasm that is determined to be a well-differentiated neuroendocrine tumor (Ki-67 ≤ 20%) with the primary tumor location known or believed to be gastroenteropancreatic origin (GEP-NET)
Disease measuring ≥ 1.5 cm in diameter on CT or MRI as measured per RECIST that shows uptake \> liver background on sstr2 PET/CT with any FDA approved sstr2 imaging agent. SSTR2 PET/CT must have been obtained within 90 days prior to scheduled C1D1 of Lutathera.
Recommended to receive LUTATHERA® therapy for unresectable and/or metastatic neuroendocrine disease.
Adequate performance status (ECOG of 0 or 1; or Karnofsky performance status of ≥70).
Agrees to contraception during therapy.
Neutrophil count within normal limits within 28 days of treatment day 1.
Platelet count within normal limits within 28 days of treatment day 1.
Ability to take oral medication and be willing to adhere to the treatment regimen
For individuals of reproductive potential: agreement to use effective birth control
Agreement to adhere to Lifestyle Considerations throughout study duration: abstain from caffeine or xanthine-containing products as well as alcohol before the start of cycle dosing and through the cycle's final blood sample; minimize social interactions during low blood counts.

Exclusion Criteria

Individuals who are pregnant or lactating (note: potential participants should not engage in 'pump \& dump' strategy; lactation must be discontinued).
Uncontrolled intercurrent illness including, but not limited to, ongoing or active infection (requiring inpatient admission or a delay to start of therapy), fever, symptomatic congestive heart failure, unstable angina pectoris, cardiac arrhythmia, or psychiatric illness/social situations that would limit compliance with study requirements.
Surgery, radiation therapy, or chemotherapy ≤ 4 weeks of C1D1 (Toxicities from prior therapies should have resolved to ≤ CTCAE grade 1 or a new baseline established).
Prior peptide-receptor radiotherapy (PRRT).
Therapeutic investigational drug within 4 weeks of C1D1 (imaging agents are acceptable).
A concurrent malignancy that, in the opinion of the investigator, would cause a safety risk by delaying therapy or confound/negatively impact study objectives (documentation of the rationale must be provided)
Prior external beam radiation dose to the kidneys of \>10 Gy (mean dose to functional renal volume).
Prior external beam radiation (including brachytherapy) involving 25% of the bone marrow (excluding scatter doses of ≤ 5 Gy) as estimated by a radiation oncologist.
History of allergic reactions attributed to compounds of similar chemical or biologic composition to Octreoscan® or Netspot™.

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in Iowa City?

Yes, this clinical trial (NCT06395402) has an active research site in Iowa City, IA that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Neuroendocrine Tumors Treatment Options in Iowa City, IA

If you're searching for neuroendocrine tumors treatment options in Iowa City, IA, this clinical trial (NCT06395402) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our Iowa City research site is actively enrolling participants for this phase 2 clinical trial. You'll receive care from experienced neuroendocrine tumors specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all neuroendocrine tumors clinical trials near you to find additional studies recruiting in your area.

More Neuroendocrine Tumors Trials in Iowa City, IA

See all neuroendocrine tumors clinical trials recruiting in Iowa City — not just this study.

Browse Neuroendocrine Tumors Trials in Iowa City →

Browse More Trials by Condition

Neuroendocrine Tumors TrialsAll Conditions →

Ready to Join in Iowa City?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · Iowa City, IA